CAAS
FLGT icon

Capital Asset Advisory Services’s Fulgent Genetics FLGT Stock Holding History

Capital Asset Advisory Services’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-650
Closed -$34K – 956
2020
Q4 		$34K Buy
+650
New +$27.2K 0.01% 705

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Asset Advisory Services's FLGT Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Fulgent Genetics (FLGT) in Q1 2021, closing a stake of 650 shares — an estimated $34K sold.

Capital Asset Advisory Services first reported a position in FLGT in Q4 2020 and held it in 1 quarter. The position peaked at $34K in Q4 2020. 256 funds tracked by Wall St. Rank hold FLGT as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Fulgent Genetics position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 650 Fulgent Genetics shares in Q1 2021, an estimated $34K.
  • Capital Asset Advisory Services first reported a position in Fulgent Genetics in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Fulgent Genetics position peaked at $34K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.